Regorafenib as treatment for patients with advanced hepatocellular cancer.

Regorafenib as treatment for patients with advanced hepatocellular cancer.

Future Oncol. 2017 Aug 02;:

Authors: Thillai K, Srikandarajah K, Ross P

Abstract
Hepatocellular carcinoma is one of the fastest growing causes of cancer-related mortality worldwide. Sorafenib was the first and only drug to improve survival for patients with advanced disease, and has been the cornerstone of treatment for nearly a decade. Regorafenib is a multikinase inhibitor that has recently been shown to significantly improve survival in patients who have progressed on first-line sorafenib. In this review, we discuss the pharmacokinetic and pharmacodynamics properties of regorafenib and its efficacy and tolerability in patients with advanced hepatocellular carcinoma.

PMID: 28766967 [PubMed - as supplied by publisher]

from #PM All via ola Kala on Inoreader http://ift.tt/2u3pGzI